{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:14:38Z","timestamp":1792804478862,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The lack of consensual measures to monitor core change in Autism Spectrum Disorder (ASD) or response to interventions leads to difficulty to prove intervention efficacy on ASD core symptoms. There are no universally accepted outcome measures developed for measuring changes in core symptoms. However, the CARS (Childhood Autism Rating Scale) is one of the outcomes recommended in the EMA Guideline on the clinical development of medicinal products for the treatment of ASD. Unfortunately, there is currently no consensus on the response definition for CARS among individuals with ASD. The aim of this elicitation process was to determine an appropriate definition of a response on the CARS2 scale for interventions in patients with Autism Spectrum Disorder (ASD). An elicitation process was conducted following the Sheffield Elicitation Framework (SHELF). Five experts in the field of ASD and two experts in expert knowledge elicitation participated in an 1-day elicitation workshop. Experts in ASD were previously trained in the SHELF elicitation process and received a dossier of scientific evidence concerning the topic. The response definition was set as the mean clinically relevant improvement averaged over all patients, levels of functioning, age groups and clinicians. Based on the scientific evidence and expert judgment, a normal probability distribution was agreed to represent the state of knowledge of this response with expected value 4.03 and standard deviation 0.664. Considering the remaining uncertainty of the estimation and the available literature, a CARS-2 improvement of 4.5 points has been defined as a threshold to conclude to a response after an intervention. A CARS-2 improvement of 4.5 points could be used to evaluate interventions' meaningfulness in indivudals. This initial finding represents an important new benchmark and may aid decision makers in evaluating the efficacy of interventions in ASD.<\/jats:p>","DOI":"10.1007\/s00787-021-01772-z","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T06:03:56Z","timestamp":1617775436000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Response (minimum clinically relevant change) in ASD symptoms after an intervention according to CARS-2: consensus from an expert elicitation procedure"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7568-568X","authenticated-orcid":false,"given":"Lucie","family":"Jurek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Baltazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheffali","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Novakovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Oakley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"O\u2019Hagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"1772_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association, editor (2013) Diagnostic and statistical manual of mental disorders: DSM-5. 5. ed. Washington, DC: American Psychiatric Publishing","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1772_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1365-2788.2010.01359.x","volume":"55","author":"I Magiati","year":"2011","unstructured":"Magiati I, Moss J, Yates R, Charman T, Howlin P (2011) Is the autism treatment evaluation checklist a useful tool for monitoring progress in children with autism spectrum disorders?: Is the autism treatment evaluation checklist useful? J Intellect Disabil Res 55:302\u2013312. https:\/\/doi.org\/10.1111\/j.1365-2788.2010.01359.x","journal-title":"J Intellect Disabil Res"},{"key":"1772_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1177\/1362361319854641","volume":"24","author":"U Provenzani","year":"2020","unstructured":"Provenzani U, Fusar-Poli L, Brondino N, Damiani S, Vercesi M, Meyer N et al (2020) What are we targeting when we treat autism spectrum disorder? A systematic review of 406 clinical trials. Autism 24:274\u2013284. https:\/\/doi.org\/10.1177\/1362361319854641","journal-title":"Autism"},{"key":"1772_CR4","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s10803-013-1798-7","volume":"43","author":"EE Bolte","year":"2013","unstructured":"Bolte EE, Diehl JJ (2013) Measurement tools and target symptoms\/skills used to assess treatment response for individuals with autism spectrum disorder. J Autism Dev Disord 43:2491\u20132501. https:\/\/doi.org\/10.1007\/s10803-013-1798-7","journal-title":"J Autism Dev Disord"},{"key":"1772_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10803-011-1280-3","volume":"42","author":"AB Cunningham","year":"2012","unstructured":"Cunningham AB (2012) Measuring change in social interaction skills of young children with autism. J Autism Dev Disord 42:593\u2013605. https:\/\/doi.org\/10.1007\/s10803-011-1280-3","journal-title":"J Autism Dev Disord"},{"key":"1772_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/aur.2257","volume":"13","author":"L Lecavalier","year":"2020","unstructured":"Lecavalier L, Bodfish J, Harrop C, Whitten A, Jones D, Pritchett J et al (2020) Development of the behavioral inflexibility scale for children with autism spectrum disorder and other developmental disabilities. Autism Res 13:489\u2013499. https:\/\/doi.org\/10.1002\/aur.2257","journal-title":"Autism Res"},{"key":"1772_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19410","volume":"19","author":"H McConachie","year":"2015","unstructured":"McConachie H, Parr JR, Glod M, Hanratty J, Livingstone N, Oono IP et al (2015) Systematic review of tools to measure outcomes for young children with autism spectrum disorder. Health Technol Assess 19:1\u2013506. https:\/\/doi.org\/10.3310\/hta19410","journal-title":"Health Technol Assess"},{"key":"1772_CR8","unstructured":"Schopler E, Van Bourgondien ME, Wellman GJ, Love SR (2010) Childhood autism rating scale, second edition. Western psychology services"},{"key":"1772_CR9","unstructured":"European Medecine Agency (2017) Guideline on the clinical development of medicinal products for the treatment of Autism Spectrum Disorder (ASD)"},{"key":"1772_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/19315864.2012.681340","volume":"6","author":"DA Geier","year":"2013","unstructured":"Geier DA, Kern JK, Geier MR (2013) A comparison of the autism treatment evaluation checklist (ATEC) and the childhood autism rating scale (CARS) for the quantitative evaluation of autism. J Ment Health Res Intellect Disabil 6:255\u2013267. https:\/\/doi.org\/10.1080\/19315864.2012.681340","journal-title":"J Ment Health Res Intellect Disabil"},{"key":"1772_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1054\/bjoc.1999.0902","volume":"82","author":"PM Fayers","year":"2000","unstructured":"Fayers PM, Cuschieri A, Fielding J, Craven J, Uscinska B, Freedman LS (2000) Sample size calculation for clinical trials: the impact of clinician beliefs. Br J Cancer 82:213\u2013219. https:\/\/doi.org\/10.1054\/bjoc.1999.0902","journal-title":"Br J Cancer"},{"key":"1772_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1740-9713.2005.00100.x","volume":"2","author":"T O\u2019Hagan","year":"2005","unstructured":"O\u2019Hagan T (2005) Elicitation. Significance 2:84\u201386. https:\/\/doi.org\/10.1111\/j.1740-9713.2005.00100.x","journal-title":"Significance"},{"key":"1772_CR13","unstructured":"Oakley JE, O\u2019Hagan T (2019) SHELF: the Sheffield Elicitation Framework (Version 4)"},{"key":"1772_CR14","doi-asserted-by":"publisher","first-page":"A141","DOI":"10.1016\/S1090-3798(99)91356-9","volume":"3","author":"MG Chez","year":"1999","unstructured":"Chez MG, Buchanan CP, Bagan BT, Hammer MS, McCarthy KS, Ovrutskaya I et al (1999) 007 Secretin and autism: A two part clinical investigation. Eur J PaediatrNeurol 3:A141. https:\/\/doi.org\/10.1016\/S1090-3798(99)91356-9","journal-title":"Eur J PaediatrNeurol"},{"key":"1772_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1067\/mpd.2001.112474","volume":"138","author":"SJ Coniglio","year":"2001","unstructured":"Coniglio SJ, Lewis JD, Lang C, Burns TG, Subhani-Siddique R, Weintraub A et al (2001) A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism. J Pediatr 138:649\u2013655. https:\/\/doi.org\/10.1067\/mpd.2001.112474","journal-title":"J Pediatr"},{"key":"1772_CR16","doi-asserted-by":"publisher","first-page":"e1056","DOI":"10.1038\/tp.2017.10","volume":"7","author":"E Lemonnier","year":"2017","unstructured":"Lemonnier E, Villeneuve N, Sonie S, Serret S, Rosier A, Roue M et al (2017) Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Transl Psychiatry 7:e1056\u2013e1056. https:\/\/doi.org\/10.1038\/tp.2017.10","journal-title":"Transl Psychiatry"},{"key":"1772_CR17","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/08830738060210060801","volume":"21","author":"R Nagaraj","year":"2006","unstructured":"Nagaraj R, Singhi P, Malhi P (2006) Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 21:450\u2013455. https:\/\/doi.org\/10.1177\/08830738060210060801","journal-title":"J Child Neurol"},{"key":"1772_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/00031305.2018.1518265","volume":"73","author":"A O\u2019Hagan","year":"2019","unstructured":"O\u2019Hagan A (2019) Expert Knowledge Elicitation: Subjective but Scientific. Am Stat 73:69\u201381. https:\/\/doi.org\/10.1080\/00031305.2018.1518265","journal-title":"Am Stat"},{"key":"1772_CR19","unstructured":"Oakley J (2020) SHELF: Tools to Support the Sheffield. Elicitation Framework. R package"},{"key":"1772_CR20","unstructured":"R Core Team (2020) R: A language and environment for statistical computing. Vienna, Austria.: R Foundation for Statistical Computing"},{"key":"1772_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1037\/0022-006X.59.1.12","volume":"59","author":"NS Jacobson","year":"1991","unstructured":"Jacobson NS, Truax P (1991) Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. J Consult ClinPsychol 59:12\u201319. https:\/\/doi.org\/10.1037\/0022-006X.59.1.12","journal-title":"J Consult ClinPsychol"},{"key":"1772_CR22","doi-asserted-by":"publisher","DOI":"10.3310\/hta18280","author":"J Cook","year":"2014","unstructured":"Cook J, Hislop J, Adewuyi T, Harrild K, Altman D, Ramsay C et al (2014) Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review. Health Technol Assess. https:\/\/doi.org\/10.3310\/hta18280","journal-title":"Health Technol Assess"}],"updated-by":[{"DOI":"10.1007\/s00787-021-01864-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000}}],"container-title":["European Child &amp; Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-021-01772-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00787-021-01772-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-021-01772-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T05:15:52Z","timestamp":1659330952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00787-021-01772-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1772"],"URL":"https:\/\/doi.org\/10.1007\/s00787-021-01772-z","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"13 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00787-021-01864-w","URL":"https:\/\/doi.org\/10.1007\/s00787-021-01864-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lucie Jurek has received honoraria from Servier. Matias Baltazar has received honoraria from Servier. He also participated in a research project sponsored by the Roche laboratory (the InFoR project). The topics and analyses of the InFoR project and those of the present paper do not compete or overlap. Sheffali Gulati has received honoraria from Servier. Neda Novakovic has received honoraria from Servier. Mar\u00eda N\u00fa\u00f1ez has received honoraria from Servier. During the completion of this paper she was funded by the Ministerio de Ciencia, Innovaci\u00f3n y Universidades (BGP18\/00,186). There is no conflict of interest with the sponsors. Jeremy Oakley has received honoraria from Servier. Tony O\u2019Hagan has received honoraria from Servier. The complete study (elicitation process and manuscript writing) was performed independently from Servier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest and sponsor\u2019s role"}}]}}